Superficial Clinical Peels

01What superficial means

A superficial peel creates a controlled injury mainly within the epidermal or very superficial skin layers, depending on the exact formulation and protocol. The treated surface then sheds or reorganises as the barrier repairs.

Superficial does not mean risk-free, and it does not mean that all visible concerns sit within reach. It describes intended treatment depth — not the quality of the decision.

02The agents are not interchangeable

Glycolic, lactic, mandelic and salicylic acids have different chemical properties and are used in different formulations. Product strength, pH, vehicle, skin preparation, area, application and exposure all affect the response.

A percentage on a bottle is therefore not a result prediction. Nor does one successful study allow every peel containing the same ingredient to inherit its outcome.

The selection begins with the target and the skin. The agent comes afterwards.

03What may be within reach

A superficial clinical peel may be considered for selected:

• rough or uneven surface texture;
• dullness where controlled exfoliation is appropriate;
• congestion;
• mild acne as part of a wider plan;
• post-acne marks;
• superficial uneven pigment;
• early sun-related surface change; and
• a regular maintenance approach where one defined treatment is more realistic than several inconsistent interventions.

These are possible treatment categories, not guarantees of suitability.

04What it does not address

A superficial peel cannot:

• add or restore facial volume;
• lift or reposition tissue;
• remove pores;
• erase structural acne scars;
• release tethered scars;
• permanently cure melasma;
• control significant inflammatory acne on its own; or
• guarantee an even pigment response.

If the principal issue is deeper texture or a target requiring planned full-field resurfacing, TCA Resurfacing may be more proportionate. A narrow deep atrophic scar needs a separate focal assessment.

05Why I use these treatments selectively

A superficial peel earns its place when a surface-level target and a smaller recovery burden genuinely fit the patient.

I use glycolic, lactic, mandelic and salicylic peels relatively rarely and selectively, when a lighter route has a clear job. Much of my peel work is built around TCA, used at different concentrations within a protocol chosen for the patient’s skin, the target and the recovery they can reasonably accept.

Sometimes regular, well-chosen surface treatment is more useful than trying five different procedures once and being unable to continue any of them. Consistency matters — but only when the treatment has a clear job.

If a superficial protocol is unlikely to produce a meaningful change, I would rather explain that than sell a low-recovery appointment for its own sake.

06Pigment risk still matters

Superficial does not mean zero-risk. In one retrospective series of 473 superficial peel treatments in skin types III–VI, PIH was recorded after 1.9% of treatments. It was a single-centre retrospective study, so that figure is not a universal personal-risk estimate.^[4]

I consider the likely diagnosis, previous PIH, melasma, active inflammation, recent tanning or sunburn, medicines, skincare, previous treatment reactions and whether reliable UVA/UVB protection is realistic.

Darker skin is not an automatic exclusion. Selected salicylic protocols have been studied in Fitzpatrick IV–VI skin, but that does not make every superficial peel appropriate for every patient. It is a reason for more exact selection and sometimes a different agent, protocol or treatment.^[2][3]

07The consultation

I assess:

• what you want to change and what is likely to be causing it;
• whether the concern is truly superficial;
• active acne or inflammation;
• skin barrier condition;
• skin tone and pigment history;
• current skincare, medicines and prescription treatment;
• cold-sore history;
• previous peels, procedures and reactions;
• current or planned UV exposure; and
• the recovery you can realistically manage.

The consultation may lead to a superficial peel, TCA resurfacing, another treatment, preparation first or no treatment.

08Preparation

Broad-spectrum UVA and UVB protection is part of the foundation. The skin barrier must be calm rather than over-exfoliated or irritated.

Some active skincare may need to be paused, but the exact instruction depends on the product and current routine. Do not stop prescribed treatment without advice from the responsible clinician.

Recent tanning, sunburn, a cold sore, infection, dermatitis flare or a new medicine can postpone the plan. A delay is better than treating skin that is not ready.

09Treatment day

The exact steps depend on the confirmed product and protocol, but the appointment normally includes:

1. checking that nothing has changed since assessment;
2. examining the skin and confirming the intended area and endpoint;
3. cleansing and product-specific preparation;
4. controlled application of the selected formulation;
5. continuous observation of the skin response;
6. completing the product-specific finishing steps; and
7. issuing written aftercare and the contact route.

Stinging, warmth or tightness may occur. This page provides no home-use concentrations, timings or layer instructions.

10Recovery

Recovery is usually lighter than after full-field TCA, but lighter does not mean invisible. Temporary redness, tightness, dryness, sensitivity and flaking may occur.

Some patients shed visibly; others do not. The result should be judged after the barrier has settled, not by how much skin comes away.

The exact return to makeup, exercise, shaving and active skincare depends on the product and how the surface looks afterwards. Your written plan owns those timings.

11Sessions and review

Superficial peels are sometimes used as a staged or regular plan because change can build gradually. That does not make completion of a prepaid course automatic.

Before committing, you should know:

• whether a single treatment or a series is being considered;
• what each appointment is intended to do;
• when response will be reviewed;
• what would justify continuing, changing or stopping;
• what happens if the skin does not respond; and
• what is included in the fee.

Treatment should answer to the skin. The skin should not answer to a package.

12The evidence, honestly

The studies below are small and protocol-specific. They do not describe every superficial peel or predict an odNOVA result.

Glycolic protocol for moderate acne

In a randomised, double-blind split-face study, 26 patients with Asian skin received one specific glycolic protocol on one side and placebo on the other.^[1]

Acne lesion counts improved significantly on the glycolic-treated side compared with placebo.

The study was small, short and limited to one protocol and population. It supports an adjunctive role for that protocol; it does not prove that every glycolic peel treats every form of acne.

Salicylic protocol for post-inflammatory pigmentation

Ten patients with Fitzpatrick IV–VI skin received one specific salicylic protocol on one side while the other side was untreated.^[2]

Patients perceived more improvement on the treated side, but blinded assessors did not find a statistically significant difference.

The small sample cannot rule out uncommon pigment or scarring complications. The honest conclusion is modest and uncertain benefit, not class-wide safety.

Small pilot in darker skin

An uncontrolled pilot followed 25 patients with Fitzpatrick V–VI skin and mixed concerns under one salicylic protocol that included a separate preparation stage.^[3]

Twenty-two of 25 participants were judged to have moderate-to-significant improvement; four reported mild adverse effects.

Because there was no control group, concerns were pooled and preparation was part of the protocol, the study cannot establish how much change came from the peel alone or prove universal safety.

13Risks and reasons to postpone

Possible effects and complications include:

• stinging, warmth, tightness, redness, dryness, swelling and flaking;
• irritation, dermatitis or acne flare;
• prolonged redness;
• post-inflammatory hyperpigmentation or lighter pigment;
• infection or cold-sore reactivation;
• delayed healing;
• scarring; and
• accidental eye exposure.

Frequency cannot responsibly be stated for superficial peels as one class. Risk depends on the actual product, formulation, skin, area, protocol and aftercare.

14When urgent help should not wait

Difficulty breathing, sudden swelling of the lips, mouth, tongue or throat, collapse, severe eye pain or a sudden change in sight are not expected recovery signs. Call 999 or go to A&E; do not wait for a clinic reply. If a problem is urgent but not life-threatening and the clinic is unavailable, contact NHS 111.

Questions, answered

15References

1. Kaminaka C, Uede M, Matsunaka H, Furukawa F, Yamamoto Y. Clinical evaluation of glycolic acid chemical peeling in patients with acne vulgaris: a randomized, double-blind, placebo-controlled, split-face comparative study. Dermatologic Surgery. 2014;40(3):314–322. doi:10.1111/dsu.12417. Accessed 4 August 2026.
2. Joshi SS, Boone SL, Alam M, et al. Effectiveness, safety, and effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin. Dermatologic Surgery. 2009;35(4):638–644. doi:10.1111/j.1524-4725.2009.01103.x. Accessed 4 August 2026.
3. Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatologic Surgery. 1999;25(1):18–22. doi:10.1046/j.1524-4725.1999.08145.x. Accessed 4 August 2026.
4. Vemula S, Maymone MBC, Secemsky EA, et al. Assessing the safety of superficial chemical peels in darker skin: a retrospective study. Journal of the American Academy of Dermatology. 2018;79(3):508–513.e2. doi:10.1016/j.jaad.2018.02.064. Accessed 4 August 2026.